News &amp; Updates

A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.

Hormone therapy use has no bearing on severe COVID-19 outcomes

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Combined treatment with dapagliflozin and spironolactone results in greater reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) than dapagliflozine alone in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Switching to DOACs may prevent stroke, bleeding in older adults

Older patients on a vitamin K antagonist (VKA) derive benefits from switching to standard-dose (SD) direct-acting oral anticoagulant (DOAC) as shown by significant decreases in stroke or systemic embolism, fatal and intracranial bleeding, and death, reveals a study.

Switching to DOACs may prevent stroke, bleeding in older adults

Prenatal SSRI, SNRI exposure linked to elevated risk of PPH

Women with prenatal exposure to selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) are at increased risk of postpartum haemorrhage (PPH), although residual confounding cannot be ruled out, as reported in a study.

Prenatal SSRI, SNRI exposure linked to elevated risk of PPH

Advancing collaboration in COVID-19 care

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

Oseltamivir for influenza helps reduce neuropsychiatric events

The use of oseltamivir for treating influenza episodes in children appears to lower the risk of serious neuropsychiatric events, according to a retrospective cohort study.

Oseltamivir for influenza helps reduce neuropsychiatric events

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

In patients with cirrhosis and upper gastrointestinal (GI) bleeds, mortality outcome does not differ between shorter and longer antibiotic prophylaxis durations, according to a systematic review and Bayesian meta-analysis.

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds